Company profile
Seroxo
Seroxo is a world-leading IVD company at the forefront of transformative technology. The LIT, a 10-minute finger-prick blood test, is a breakthrough technology that assesses real-time, 3D neutrophil function in cancer and sepsis.
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
Company registered at Companies House
1 Nov 2022 to 30 Apr 2023
Sepsis is the body's overwhelming and life-threatening response to infection that can lead to tissue damage, organ failure, and death. Medically, sepsis is your body's immune system over-responding to an infection. Key to saving lives in sepsis is detecting it early enough and managing it optimally. Seroxo has developed the Leukocyte ImmunoTest(tm) (LIT(t...
1 Jan 2022 to 31 Mar 2022
Sepsis is the body's extreme response to an infection. It is a life-threatening medical emergency that happens when an infection you already have triggers a chain reaction throughout your body. Sepsis affects approximately 250,000 people in the UK each year and leads to approximately 48,000 deaths. Early diagnosis is key to improved clinical outcomes; how...
1 Oct 2020 to 30 Nov 2021
The coronavirus pandemic of 2020 has had a huge impact on the lives of millions around the country. A particular challenge has been faced by cancer patients, who have been forced to miss regular checkups and tests over recent months because of their elevated risks of infection (the immune systems of cancer - and especially chemotherapy - patients are ofte...
